Propolis for Patients With Chronic Kidney Disease.

Universidade Federal Fluminense

Status: Completed

Conditions: Chronic Kidney Diseases; Inflammation

Treatments: Dietary Supplement: Propolis; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04411758

Denise Mafra8

Details and patient eligibility

About

To evaluate the effects of propolis extract on inflammation in participants with chronic kidney disease.

Specific objectives

To assess before and after the intervention period:

• The expression of transcription factors (nuclear factor-kB), antioxidant enzymes (heme-oxygenase-1), inflammasome receptor, peroxisome proliferator-activated receptor-γ, as well as the levels of inflammatory cytokines (IL-6, Tumor nuclear factor-α, C-reactive protein, interleukin 1) and E-selectin adhesion molecules;
• The levels of protein expression of inflammatory markers and antioxidant enzymes;
• The profile of the intestinal microbiota of stool samples from the research participants;
• Plasma levels of substances reactive to thiobarbituric acid and oxidized low density lipoprotein as a marker of oxidative stress;
• Routine and anthropometric laboratory variables, indicative of the metabolic profile of the research participants;
• Assess blood pressure, 6-minute walk test, recovery heart rate and chair lift test to assess the functional capacity of the research participants;
• Assess atherogenic risk;
• Food intake and nutritional status; Compare data between the intervention and control groups.

Full description

Chronic kidney disease (CKD) has chronic systemic inflammation as an important component of multifactorial origin, a factor related to both the progression and outcomes of CKD, being involved in all causes of mortality in these patients, such as cardiovascular disease. In this context, some nutritional strategies have been proposed as an adjuvant therapeutic alternative to modulate inflammation, starting from the consolidated knowledge of the role of nutrients and bioactive compounds on the expression of genes related to inflammation and oxidative stress, factors that feed on each other. In view of this scenario, propolis, a substance made up of a combination of several chemical components with broad potential biological activity, appears as a promising alternative to modulate inflammation in patients with CKD. However, clinical evidence to assess the effects of propolis in patients with CKD is scarce, and there are no studies that have investigated its effects on gene expression and markers related to inflammation in these patients. Thus, the present project proposes a longitudinal study of the clinical trial type that aims to evaluate the effects of propolis alcoholic extract on transcription factors and inflammatory markers in patients with CKD.

Enrollment: 24 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18 years or older

• with fistula arteriovenous

Exclusion criteria

• Patients pregnant
• Smokers
• Using antibiotics in the last three months
• Using antioxidant supplements as antioxidant vitamins, probiotic, prebiotic, symbiotic and antibiotics in the last three months
• Clinical diagnosis of infectious diseases
• Clinical diagnosis of Cancer
• Clinical diagnosis of AIDS - for PD patients - no peritonitis

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

24 participants in 2 patient groups, including a placebo group

Placebo Group

Placebo Comparator group

Description:

Patients will receive 4 capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months

Treatment:

Dietary Supplement: Placebo

Propolis Group

Experimental group

Description:

Patients will receive 4 capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months

Treatment:

Dietary Supplement: Propolis